Goldman Sachs’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Goldman Sachs’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-47,260	Closed	-$1.01M	–	6021
2024 Q1	$1.01M	Buy	47,260 +32,128	+212%	+$384K	﹤0.01%	4347
2023 Q4	$145K	Buy	+15,132	New	+$73.5K	﹤0.01%	5229
2021 Q4	–	Sell	-20,149	Closed	-$160K	–	6766
2021 Q3	$160K	Buy	20,149 +1,928	+11%	+$16.2K	﹤0.01%	5797
2021 Q2	$147K	Buy	18,221 +4,149	+29%	+$35.7K	﹤0.01%	5856
2021 Q1	$151K	Sell	14,072 -85	-0.6%	-$994	﹤0.01%	5738
2020 Q4	$166K	Buy	+14,157	New	+$178K	﹤0.01%	5154

Goldman Sachs's FUSN Position: Q2 2024 in Review

Goldman Sachs sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 47,260 shares — an estimated $1.01M sold.

Goldman Sachs first reported a position in FUSN in Q4 2020 and held it in 6 quarters. The position peaked at $1.01M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

Goldman Sachs reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
Goldman Sachs sold 47,260 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $1.01M.
Goldman Sachs first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2020 and held it in 6 quarters.
Goldman Sachs's Fusion Pharmaceuticals Inc. Common Shares position peaked at $1.01M in Q1 2024.
0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.